Background: Dedifferentiated chondrosarcomas account for approximately 10% of all chondrosarcomas. There are few reports that describe the cytologic findings in dedifferentiated chondrosarcomas. In all these cases it was only present in the smears as a high grade sarcoma component.
Case: A 58-year-old man with a bone lesion in the right acetabular zone was admitted to the hospital. The clinical diagnosis was chondrosarcoma. A fine needle aspiration biopsy was performed. The smears of the sample had different characteristics in composition. Some slides had mostly abundant chondroid matrix with low to moderate cellularity. Other slides were cellular and contained mainly pleomorphic, spindled-shaped cells. The typical appearance of dedifferentiated chondrosarcoma was present in some slides that showed focal zones with chondroid matrix adjacent to or surrounded by pleomorphic spindled cells. The composition of the surgical specimen (slightly greater cartilaginous component than the sarcomatous one) allowed us to make a straightforward diagnosis of dedifferentiated chondrosarcoma.
Conclusion: This is the first report that describes the presence of both components, high and low grade, by fine needle aspiration biopsy in dedifferentiated chondrosarcoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000325014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesenchymal Stem Cells-Derived Small Extracellular Vesicles and Their Validation as a Promising Treatment for Chondrosarcoma in a 3D Model in Vitro.
Biotechnol Bioeng
December 2024
Interdisciplinary Research Centre on Biomaterials (CRIB), University of Naples Federico II, Naples, Italy.
Chondrosarcomas (CHS) constitute approximately 20% of all primary malignant bone tumors, characterized by a slow growth rate with initial manifestation of few signs and symptoms. These malignant cartilaginous neoplasms, particularly those with dedifferentiated histological subtypes, pose significant therapeutic challenges, as they exhibit high resistance to both radiation and chemotherapy. Ranging from relatively benign, low-grade tumors (grade I) to aggressive high-grade tumors with the potential for lung metastases and a grim prognosis, there is a critical need for innovative diagnostic and therapeutic approaches, particularly for patients with more aggressive forms.
View Article and Find Full Text PDFA rare case of dedifferentiated intracranial solitary fibrous tumor with chondrosarcomatous differentiation.
Neuropathology
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
This report details a rare case of a 30-year-old female presenting with neurological symptoms, including headaches, seizures, and left-sided weakness. Imaging revealed a mass in the right parafalcine region of her brain. Surgical resection identified a tumor with two distinct components.
View Article and Find Full Text PDFLiposarcomas are the most common soft tissue sarcoma primarily originating in deep soft tissues and the retroperitoneum. Sarcoma classification includes atypical lipomatous tumor/well-differentiated liposarcoma (WDL) and dedifferentiated liposarcoma (DDL), myxoid liposarcoma, and pleomorphic liposarcoma. DDL is most prevalent in the retroperitoneum and often has two distinct components, a well-differentiated lipomatous component and a dedifferentiated nonlipomatous component that could be morphologically similar to malignant fibrous histiocytoma (MFH) or fibrosarcoma.
View Article and Find Full Text PDFRadiation-induced dedifferentiated chondrosarcoma of the chest wall.
JTCVS Tech
December 2024
Department of Burns and Plastics Surgery, Morriston Hospital, Swansea, Wales, United Kingdom.
Advancing Systemic Therapy in Chondrosarcoma: New Horizons.
Oncol Ther
December 2024
Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UK.
Article Synopsis
- The treatment of advanced chondrosarcoma, which often doesn't respond well to standard chemotherapy, is currently being explored through targeted therapies aimed at specific genetic mutations and signaling pathways.
- New strategies include utilizing IDH inhibitors for tumors with IDH mutations, hedgehog pathway inhibitors, and various forms of immunotherapy, all facing challenges but showing potential for effectiveness.
- There's a strong emphasis on using personalized, multi-omics approaches to create combination therapies that can better address the heterogeneous nature of chondrosarcoma and possibly improve treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!